anti-BCMA/anti-CD3 bispecific antibody EMB-06
Term · Oncology and biomedicine · MLC-T-ONC-010163
A tetravalent, bispecific antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-BCMA/anti-CD3 bispecific antibody EMB-06 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. In EMB-06, the two antigen-binding fragments (Fabs) are fused directly in a crisscross orientation resulting in four active and independent antigen binding sites.
| Identifier | MLC-T-ONC-010163 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-BCMA/CD3 bispecific antibody EMB-06; BCMAxCD3 bispecific antibody EMB-06; anti-BCMA/anti-CD3 FIT-Ig bispecific antibody EMB-06; Fabs-in-tandem immunoglobulin bispecific antibody EMB-06 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010163",
"term": "anti-BCMA/anti-CD3 bispecific antibody EMB-06",
"field": "Oncology and biomedicine",
"definition": "A tetravalent, bispecific antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-BCMA/anti-CD3 bispecific antibody EMB-06 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. In EMB-06, the two antigen-binding fragments (Fabs) are fused directly in a crisscross orientation resulting in four active and independent antigen binding sites.",
"synonyms": [
"anti-BCMA/CD3 bispecific antibody EMB-06",
"BCMAxCD3 bispecific antibody EMB-06",
"anti-BCMA/anti-CD3 FIT-Ig bispecific antibody EMB-06",
"Fabs-in-tandem immunoglobulin bispecific antibody EMB-06"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-bcma-anti-cd3-bispecific-antibody-emb-06/"
}
Record 1,237 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.